COMP <GO>
STLN vs SRTA // REVENUE GROWTH (YOY)
Starling Oncology Inc. (NASDAQ) VS. Strata Critical Medical Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: STLN 5
— SRTA 4
▲ REVENUE GROWTH (YOY) LEADER: SRTA
LAST: $6.65 (+0.15%) • MKT CAP: $677.7M
revenue-growth
27.80%
LAST: $4.75 (-0.21%) • MKT CAP: $420.2M
revenue-growth
34.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (STLN VS. SRTA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | STLN | SRTA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 20.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -7.10% | -27.90 | SRTA | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.10% | -13.92% | +9.82 | STLN | /fcf-yield <GO> |
| Operating Margin | -7.20% | -11.30% | +4.10 | STLN | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 21.00% | +47.00 | STLN | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 27.80% | 34.30% | -6.50 | SRTA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.58 | 5.58 | -3.00 | SRTA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 4/9 | -1.00 | SRTA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.5 | 36.4 | +13.05 | STLN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 8.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $677.7M | $420.2M | $257.5M | STLN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | STLN REV | SRTA REV | STLN GROSS % | SRTA GROSS % | STLN FCF | SRTA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $502.7M | $197.1M | — | 20.9% | -$27.8M | -$58.5M |
| FY 2024 | $393.4M | $146.8M | — | 20.2% | -$30.3M | -$33.4M |
| FY 2023 | $324.2M | $225.2M | — | — | -$36.3M | -$32.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
STLN // BETA —
SRTA // BETA —